Grace Therapeutics, Inc. (GRCE)
NASDAQ: GRCE · Real-Time Price · USD
3.820
-0.240 (-5.91%)
Dec 20, 2024, 4:00 PM EST - Market closed
Grace Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
38.73M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Rapid Micro Biosystems | 26.17M |
| ImmuCell | 23.84M |
| Lucid Diagnostics | 4.19M |
| CollPlant Biotechnologies | 650.00K |
| Exicure | 500.00K |
| Cardio Diagnostics Holdings | 35.69K |
| Q32 Bio | -14.66M |
GRCE News
- 2 months ago - Acasti Announces Corporate Name Change to Grace Therapeutics, Inc. - GlobeNewsWire
- 3 months ago - Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104 - GlobeNewsWire
- 3 months ago - Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 4 months ago - Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update - GlobeNewsWire
- 6 months ago - Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial - GlobeNewsWire
- 6 months ago - Acasti Announces Year-End 2024 Financial Results, Provides Business Update - GlobeNewsWire
- 7 months ago - Acasti Pharma to Attend BIO International Convention 2024 - GlobeNewsWire
- 11 months ago - Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights - GlobeNewsWire